XCell Therapeutics Inc
KOSDAQ:373110
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
X
|
XCell Therapeutics Inc
KOSDAQ:373110
|
KR |
|
L
|
Lea Bank ASA
OSE:LEA
|
NO |
|
Welspun Specialty Solutions Ltd
BSE:500365
|
IN |
|
Tritax Big Box Reit PLC
LSE:BBOX
|
UK |
|
Reliv International Inc
OTC:RELV
|
US |
|
G
|
Great Northern Minerals Ltd
XBER:3GW
|
AU |
|
Y
|
Yangtze River Port and Logistics Ltd
OTC:YRIV
|
US |
|
H
|
Haemonetics Corp
XMUN:HAZ
|
US |
Bankruptcy Probability
XCell Therapeutics Inc's probability of bankruptcy is Hidden . The solvency score is Hidden .
We take all the information about a company's solvency, such as how easily it can pay interest on outstanding debt, how much cash it has, the amount of debt, and more, and use it to estimate the probability of bankruptcy.
Financial Position
| Mar 31, 2026 | 6.3B |
| Dec 31, 2025 | 6.6B |
| Sep 30, 2025 | 923m |
| Jun 30, 2025 | 3.4B |
| Mar 31, 2026 | 313.9m |
| Dec 31, 2025 | 879.6m |
| Sep 30, 2025 | 992.1m |
| Jun 30, 2025 | 1.1B |
| Mar 31, 2026 | 4.8B |
| Dec 31, 2025 | 4.9B |
| Sep 30, 2025 | 5.8B |
| Jun 30, 2025 | 5B |
Solvency Ratios
Solvency Ratios Comparison
XCell Therapeutics Inc Competitors
| Country | Company | Market Cap | D/E | D/A |
Interest Coverage |
Altman Z-Score |
Quick Ratio |
Current Ratio |
Cash Ratio |
||
|---|---|---|---|---|---|---|---|---|---|---|---|
| KR |
X
|
XCell Therapeutics Inc
KOSDAQ:373110
|
21.4B KRW |
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
|
| FR |
|
Pharnext SCA
OTC:PNEXF
|
6T USD |
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
|
| JP |
|
Takara Bio Inc
TSE:4974
|
120.4T JPY |
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
|
| US |
|
Abbvie Inc
NYSE:ABBV
|
456.2B USD |
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
|
| US |
|
Amgen Inc
NASDAQ:AMGN
|
236.4B USD |
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
|
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
184.7B USD |
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
|
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
138.7B USD |
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
|
| US |
E
|
Epizyme Inc
F:EPE
|
94.1B EUR |
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
|
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
83.5B USD |
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
|
| NL |
|
argenx SE
XBRU:ARGX
|
56B EUR |
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
|
| AU |
|
CSL Ltd
ASX:CSL
|
82.5B AUD |
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
Loading...
|
XCell Therapeutics Inc's probability of bankruptcy is Hidden .
The probability of bankruptcy is estimated using credit risk models that assess financial health, debt levels, interest coverage, and other solvency indicators.
As of the latest report, XCell Therapeutics Inc has total debt of 4.8B KRW. This includes both short-term (3.5B KRW) and long-term (1.3B KRW) debt.
You can find a full breakdown on its Balance Sheet.
